Cargando…

Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease

Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui-Fang, Ho, Philip Wing-Lok, Leung, Gideon Chi-Ting, Lam, Colin Siu-Chi, Pang, Shirley Yin-Yu, Li, Lingfei, Kung, Michelle Hiu-Wai, Ramsden, David Boyer, Ho, Shu-Leong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241661/
https://www.ncbi.nlm.nih.gov/pubmed/28098219
http://dx.doi.org/10.1038/srep40887
_version_ 1782496222819385344
author Liu, Hui-Fang
Ho, Philip Wing-Lok
Leung, Gideon Chi-Ting
Lam, Colin Siu-Chi
Pang, Shirley Yin-Yu
Li, Lingfei
Kung, Michelle Hiu-Wai
Ramsden, David Boyer
Ho, Shu-Leong
author_facet Liu, Hui-Fang
Ho, Philip Wing-Lok
Leung, Gideon Chi-Ting
Lam, Colin Siu-Chi
Pang, Shirley Yin-Yu
Li, Lingfei
Kung, Michelle Hiu-Wai
Ramsden, David Boyer
Ho, Shu-Leong
author_sort Liu, Hui-Fang
collection PubMed
description Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity. Here, we explored the interplay amongst these factors using mutant LRRK2(R1441G) (leucine-rich-repeat-kinase-2) knockin mice. We found that mutant primary cortical and mesencephalic dopaminergic neurons were more susceptible to rotenone-induced ATP deficiency and cell death. Compared with wild-type controls, striatal synaptosomes isolated from young mutant mice exhibited significantly lower dopamine uptake after rotenone toxicity, due to reduced striatal synaptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels. Mutant mice developed greater locomotor deficits in open-field tests than wild-type mice following low oral rotenone doses given twice weekly over 50 weeks (half their lifespan). The increased locomotor deficit was associated with specific reduction in striatal mitochondrial Complex-I (NDUFS4) in rotenone-treated mutant but not in similarly treated wild-type mice. Our unique experimental model which incorporates genetic effect, natural aging and prolonged oral environmental toxicity administered to mutant knockin LRRK2 mice over half their life span, with observable and measurable phenotype, is invaluable in further studies of the pathogenic process and therapeutics of PD.
format Online
Article
Text
id pubmed-5241661
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52416612017-01-23 Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease Liu, Hui-Fang Ho, Philip Wing-Lok Leung, Gideon Chi-Ting Lam, Colin Siu-Chi Pang, Shirley Yin-Yu Li, Lingfei Kung, Michelle Hiu-Wai Ramsden, David Boyer Ho, Shu-Leong Sci Rep Article Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity. Here, we explored the interplay amongst these factors using mutant LRRK2(R1441G) (leucine-rich-repeat-kinase-2) knockin mice. We found that mutant primary cortical and mesencephalic dopaminergic neurons were more susceptible to rotenone-induced ATP deficiency and cell death. Compared with wild-type controls, striatal synaptosomes isolated from young mutant mice exhibited significantly lower dopamine uptake after rotenone toxicity, due to reduced striatal synaptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels. Mutant mice developed greater locomotor deficits in open-field tests than wild-type mice following low oral rotenone doses given twice weekly over 50 weeks (half their lifespan). The increased locomotor deficit was associated with specific reduction in striatal mitochondrial Complex-I (NDUFS4) in rotenone-treated mutant but not in similarly treated wild-type mice. Our unique experimental model which incorporates genetic effect, natural aging and prolonged oral environmental toxicity administered to mutant knockin LRRK2 mice over half their life span, with observable and measurable phenotype, is invaluable in further studies of the pathogenic process and therapeutics of PD. Nature Publishing Group 2017-01-18 /pmc/articles/PMC5241661/ /pubmed/28098219 http://dx.doi.org/10.1038/srep40887 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Liu, Hui-Fang
Ho, Philip Wing-Lok
Leung, Gideon Chi-Ting
Lam, Colin Siu-Chi
Pang, Shirley Yin-Yu
Li, Lingfei
Kung, Michelle Hiu-Wai
Ramsden, David Boyer
Ho, Shu-Leong
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title_full Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title_fullStr Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title_full_unstemmed Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title_short Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
title_sort combined lrrk2 mutation, aging and chronic low dose oral rotenone as a model of parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241661/
https://www.ncbi.nlm.nih.gov/pubmed/28098219
http://dx.doi.org/10.1038/srep40887
work_keys_str_mv AT liuhuifang combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT hophilipwinglok combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT leunggideonchiting combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT lamcolinsiuchi combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT pangshirleyyinyu combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT lilingfei combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT kungmichellehiuwai combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT ramsdendavidboyer combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease
AT hoshuleong combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease